NASDAQ · Biotechnology

Insmed Incorporated (INSM) Stock

$101.49 -1.58% NASDAQ: INSM Healthcare

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen.

Valuation

MetricValue
Price$101.49
Market Cap$22.00B
P/E Ratio347.67
P/B Ratio33.63
P/S Ratio28.86
EPS (TTM)$0.81
52-Week High$212.75
52-Week Low$64.85
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-2.94%
ROA-31.11%
ROCE-159.27%
Gross Margin81.81%
Operating Margin-65.46%
Net Margin-1.44%
Debt/Equity1.06
Current Ratio4.47

Annual Financials (USD)

Metric20212022202320242025
Revenue$188.0M$245.0M$305.0M$364.0M$606.0M
Operating Profit$-375.0M$-457.0M$-710.0M$-878.0M$-1.2B
Net Profit$-435.0M$-482.0M$-750.0M$-914.0M$-1.3B
EPS$-3.88$-3.91$-5.34$-5.57$-6.41
Op Margin-199.0%-186.4%-232.5%-241.5%-194.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.2B$1.7B$1.3B$2.0B$2.3B
Total Liabilities$833.0M$1.6B$1.7B$1.7B$1.5B
Cash$717.0M$1.1B$482.0M$555.0M$510.0M
Borrowings$612.0M$1.2B$1.2B$1.3B$768.0M

Latest News

Insmed Insider Sold Shares Worth $1,256,084, According to a Recent SEC Filing MT Newswires · Jul 10, 2026 Insmed Insider Sold Shares Worth $1,352,932, According to a Recent SEC Filing MT Newswires · Jul 8, 2026 Here’s Why TimesSquare Mid Cap Growth Strategy Added Insmed (INSM) Insider Monkey · Jul 1, 2026 Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors GlobeNewswire · Jun 30, 2026 Mizuho Maintains an Outperform Rating on Insmed Incorporated (INSM) Insider Monkey · Jun 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-363.0M$-400.0M$-536.0M$-684.0M$-935.0M
Investing Cash Flow$-72.0M$-44.0M$-237.0M$-605.0M$-97.0M
Financing Cash Flow$6.0M$152.0M$17.0M$110.0M$0
Net Cash Flow$184.0M$357.0M$-592.0M$73.0M$-45.0M
Free Cash Flow$-371.0M$-410.0M$-550.0M$-706.0M$-968.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.09
EV / EBITDA-25.99
FCF Yield-3.78%
Quick Ratio4.10
Interest Coverage-14.01
Return 1Y5.68%
Return 3Y415.28%
Return 5Y334.13%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Insmed Incorporated

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.

Insmed Incorporated is led by CEO William H. Lewis, employs 1,271 people, headquartered in Bridgewater, US, publicly traded since 2000.

Insmed Incorporated (INSM) stock trades at $101.49 with a market capitalization of $22.00B. The stock is valued at a price-to-earnings (P/E) ratio of 347.67, price-to-book of 33.63, price-to-sales of 28.86. Over the past 52 weeks the stock has ranged between $64.85 and $212.75, and currently trades 52.3% below its 52-week high.

On profitability, Insmed Incorporated generates a return on equity (ROE) of -2.94%, return on capital employed of -159.27%, an operating margin of -65.46%, a net profit margin of -1.44%.

In its most recent fiscal year, Insmed Incorporated reported annual revenue of $606.0M, net profit of $-1.3B, revenue has compounded at 29.9% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 1.06, a current ratio of 4.47, total assets of $2.3B, $510.0M in cash and equivalents.

INSM has an average daily trading volume of 3,904,375 shares, a beta of 0.77 (less volatile than the overall market).

Official website: www.insmed.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides